Estimated reading time: 14 minutes
Key Takeaways
- Nicotine can produce short-term improvements in attention and alertness, but there is no strong evidence that it enhances long-term cognition in healthy individuals.
- Regular use leads to dependence, meaning any initial cognitive benefits are quickly offset by addiction and the need to maintain baseline function.
- Claims that usage of nicotine pouches prevents or reverses Alzheimer’s disease are not supported by clinical evidence and largely stem from misinterpreted correlations.
- While smoking has been associated with lower Parkinson’s rates in some studies, nicotine itself has not shown consistent benefits in clinical trials.
- Nicotine is not harmless even in non-smoking forms, as it increases heart rate, blood pressure, and overall cardiovascular risk.
- Individual genetic differences, especially in the CYP2A6 gene, significantly influence how nicotine affects addiction risk and overall impact on the body.
Scroll through TikTok or any biohacking community these days, and you will encounter a familiar sequence: a confident influencer, often invoking statements like “do your own research” or “what Big Pharma doesn’t want you to know,” holds up a tin of nicotine pouches and makes an extraordinary claim.
Nicotine, they say, reverses Alzheimer’s disease. It protects the brain against Parkinson’s. It sharpens cognition, boosts productivity, extends lifespan, and optimizes male vitality.
It is easy to see the appeal of these claims. Many people are drawn to the idea of natural or alternative solutions, seeking ways to improve their health outside mainstream pharmaceutical options.
In an era of growing skepticism toward traditional medical advice, the promise of a plant-derived compound that offers both cognitive benefits and protection against disease taps directly into the wishes and worries of wellness-focused consumers.
The wellness world, with its appetite for the counterintuitive and its distrust of mainstream medicine, has found a new darling. And this time, it is one of the most addictive substances known to human biology.
The trend is not fringe. Prominent figures, including biohacker Dave Asprey, celebrity trainer Jillian Michaels, podcaster Andrew Huberman, and even US Health Secretary Robert F. Kennedy Jr. have lent credibility to this idea[1].
Nicotine, separated from the carcinogens in cigarette smoke, might be a legitimate health tool.
Current use of nicotine pouches by youth and young adults increased nearly fourfold between July - October 2022 and February - June 2025[2].
This article aims to deep-dive into each claim and explain what peer-reviewed science actually says.
Understanding the Trend: Where It Comes From
The current wave of nicotine enthusiasm is best understood in context.
As smoking rates have fallen sharply in the United States and globally[3], tobacco and nicotine companies have pivoted aggressively toward smokeless products: pouches, patches, gums, and lozenges.
These products are advertised as ways to consume nicotine without the cancer-causing chemicals in cigarette smoke.
Into this commercial landscape stepped a ready-made cultural movement.
The Make America Healthy Again (MAHA) movement, which has gathered considerable momentum since 2024, encourages its followers to question medical consensus and embrace “natural” alternatives suppressed by pharmaceutical interests.
Within this system, nicotine, a compound found in plants, has been recast as a misunderstood gift of nature.
- Asprey, who has invested in the nicotine pouch company Lucy and has done consulting work for Philip Morris, has called nicotine one of “Mother Nature’s cognitive enhancers.” Further, he has encouraged his followers to conduct self-experiments[1].
- Jillian Michaels has discussed using low-dose nicotine to protect against Parkinson’s disease and Alzheimer’s[1].
- Tucker Carlson, who sells his own nicotine pouch brand, has called products like ZYN “lifesaving[4].”
What unites these voices is a rhetorical strategy: frame nicotine as a substance that mainstream medicine has unfairly demonized and position self-experimentation as an act of intellectual courage.
The same framing has been applied to raw milk, beef tallow, and peptides in the MAHA ecosystem.
The problem, of course, is that a compelling narrative is not the same as evidence.
Claim 1: Nicotine Sharpens the Mind and Enhances Cognition
What Influencers Say
Andrew Huberman has repeatedly claimed that nicotine “sharpens the mind” and makes users more alert. Dave Asprey has made broader claims about cognitive enhancement and increased productivity. The general argument is that nicotine, by stimulating nicotinic acetylcholine receptors (nAChRs) in the brain, produces measurable improvements in attention, focus, and memory.
What the Science Says
It is true that nicotine acts on nicotinic acetylcholine receptors throughout the brain[5].
These receptors play important roles in attention, working memory, and executive function.
Acute nicotine administration does produce short-term improvements in certain cognitive tasks, particularly attention and reaction time.
This pharmacological effect is real and well-documented.
However, numerous caveats undermine the biohacker narrative:
- The benefits are primarily acute and temporary.
A 2025 medRxiv preprint evaluating data from over 500,000 participants in the UK Biobank found no clear evidence that nicotine improves fluid intelligence or long-term cognitive outcomes[6].
The authors noted that prior studies showing cognitive enhancement “involve short-term administration of nicotine, and therefore any beneficial impact nicotine has on cognition is likely to be acute and temporary and does not reflect lifelong exposure to nicotine.”
- The benefits in healthy non-smokers are weak.
A review published in PMC (NIH) found that while nicotine improved working memory in those who stopped using cigarettes, the same was not observed in non-smokers who started smoking. In other words, nicotine may simply be restoring function in those undergoing withdrawal, not creating a net gain in healthy brains[7].
- Industry funding distorts the research base.
A systematic review published in Substance Abuse: Research and Treatment found that tobacco industry funding was significantly correlated with positive outcomes in cognitive performance studies. This is the same methodological problem that plagued sugar industry research on dietary fat for decades[8].
- Chronic use creates dependency, not enhancement.
Jonathan Foulds, professor of public health sciences and psychiatry at Penn State College of Medicine, put it plainly: “It doesn’t make you more intelligent, it doesn’t make you funnier, it doesn’t make you able to write interesting novels, or any of those things. It makes you able to focus on boring situations and stay with the topic a little bit longer.[1]”
Over time, regular users develop tolerance and dependence, losing the ability to concentrate without nicotine, which is a net cognitive loss, not gain.
Chronic nicotine exposure leads to desensitization of nicotinic receptors, which in turn makes the receptors less responsive to nicotine upon binding, attenuating the cognitive-enhancing effects over time.
— MedRxiv, 2025 — UK Biobank Large-Scale Analysis
Claim 2: Nicotine Protects Against Alzheimer’s Disease
What Influencers Say
Dave Asprey has claimed nicotine can “reverse Alzheimer’s disease.”
Jillian Michaels says she uses it specifically to protect against Alzheimer’s.
This is perhaps the most serious and potentially harmful of all the claims, because it could lead people with cognitive concerns to self-medicate with an addictive substance instead of seeking appropriate medical evaluation.
What The Science Says
The Alzheimer’s claim is based on a real but deeply misrepresented observation.
Epidemiological studies have historically shown that smokers have lower rates of Alzheimer’s disease diagnosis[9].
Influencers have seized on this correlation and attributed the effect to nicotine.
There are multiple problems with this reasoning:
- Smokers Die Younger.
One of the most significant confounders in the smoking-Alzheimer’s correlation is that smokers have dramatically shorter life expectancies due to cancer, cardiovascular disease, and other tobacco-related conditions.
Since Alzheimer’s is primarily a disease of late age, smokers may simply not live long enough to receive a diagnosis. This is a survivorship bias problem, not evidence of neuroprotection.
- Smoking as a whole increases dementia risk.
The World Health Organization[10] and multiple meta-analyses have concluded that overall tobacco smoking is associated with a higher risk of dementia and cognitive decline[11], the exact opposite of what influencers claim.
The cardiovascular damage caused by smoking accelerates cognitive deterioration over time.
- Clinical trials on nicotine for Alzheimer's have been inconclusive.
A Cochrane systematic review, the gold standard of evidence-based medicine, explicitly concluded that it was "not able to provide reliable evidence that nicotine is a useful treatment for Alzheimer's disease[12]."
The few small studies showing modest short-term effects on some cognitive tests have not been reproduced at scale.
The bottom line: The Alzheimer's claim is based on a misread of epidemiological correlation, filtered through survivorship bias, and contradicted by both clinical trial data and the researchers whose work is being cited.
Claim 3: Nicotine Protects Against Parkinson’s Disease
What Influencers Say
Jillian Michaels has specifically mentioned Parkinson’s protection as a reason for her nicotine use.
The epidemiological observation underlying this claim is real: studies have consistently found that smokers have lower rates of Parkinson’s disease[13].
What the Science Says
The Parkinson’s-smoking correlation is one of the most replicated findings in epidemiology, and scientists have taken it seriously.
There is credible laboratory evidence that nicotine interacts with nicotinic acetylcholine receptors in ways that may protect dopaminergic neurons, the neurons whose loss drives Parkinson’s[14].
Animal studies have shown some neuroprotective effects.
But translating this into a health recommendation for healthy people requires several leaps that the evidence does not support:
- Correlation does not establish causation.
The lower Parkinson’s rates in smokers may be driven by genetic factors, by other compounds in tobacco smoke (not nicotine specifically), or again by survivorship bias. The genetic architecture of Parkinson’s risk is complex, and several variants affecting dopamine pathways are also correlated with reduced smoking behavior, suggesting reverse causation rather than protection.
- Clinical trials on nicotine patches for Parkinson’s have not been impressive.
When researchers moved from epidemiology to controlled trials, the results were disappointing. Nicotine patches have not clearly slowed Parkinson’s progression or reliably improved symptoms in clinical settings[15].
No regulatory body recommends nicotine for Parkinson’s prevention.
Not the American Academy of Neurology, not the National Institute on Aging, not any major clinical body.
If the evidence were sufficient, clinicians would be recommending it.
The Parkinson’s claim is the strongest-sounding of all the nicotine biohacking arguments, and even here, the actual clinical evidence falls dramatically short of the confident assertions made on social media.
The Real Risks: What Influencers Are Downplaying
The biohacking narrative around nicotine relies on a rhetorical sleight of hand: separating nicotine from cigarette smoke and presenting it as a benign, natural compound.
It is true that nicotine pouches and patches carry far lower cancer risk than combustible tobacco because cancer risk is driven primarily by the tar and the thousands of chemicals generated by burning tobacco.
But “safer than cigarettes” is an extremely low bar, and it is not the same as safe.
Addiction: The Primary Risk
Nicotine is one of the most addictive substances known to science[16].
It acts on the brain’s reward circuitry by releasing dopamine, creating powerful reinforcement loops that become progressively harder to break.
Studies note that users can begin showing signs of addiction quickly, sometimes even before they establish a regular daily habit[17].
Critically, the “focus boost” that attracts non-smokers to nicotine is partly pharmacological and partly the relief of early withdrawal.
As tolerance builds, the brain requires nicotine simply to function at baseline.
The YouTuber Mark Dohner, who started nicotine pouches after hearing Huberman recommend them, became so dependent that attempting to go a single day without nicotine caused brain fog severe enough to force him to pull over while driving[1].
This is not an edge case. It is the predictable pharmacological outcome of regular nicotine use.
Cardiovascular Risk
A 2026 European Heart Journal review confirmed that endothelial dysfunction, an early marker of cardiovascular disease, occurs consistently across all nicotine delivery systems, not just cigarettes.
Nicotine activates the sympathetic nervous system, raises heart rate and blood pressure, induces oxidative stress, and reduces nitric oxide availability[18].
The review noted that the European Society of Cardiology stated in 2024 that "no form of nicotine use is safe for cardiovascular health,” a position aligned with the American Heart Association's policy statement.
They found that smokeless oral nicotine products have "potential adverse effects on biomarkers of cardiovascular risk" and increased mortality risk in people with existing heart or cerebrovascular disease[19].
Harvard researchers have specifically warned that nicotine in products like ZYN "may increase cardiovascular disease risk in people not already using nicotine products,” the exact population the biohacking trend is recruiting[20].
Young And Developing Brains
A 2025 Frontiers in Public Health review found that nicotine pouches are proliferating rapidly among teens and young adults.
This population is especially vulnerable because the brain continues developing until the mid-twenties.
Nicotine disrupts the development of the prefrontal cortex, the region governing impulse control, planning, and executive function, and substantially increases long-term addiction susceptibility.
The cardiovascular effects in adolescents are also concerning, with nicotine triggering sympathetic nervous system activation and elevation of both heart rate and blood pressure in developing cardiovascular systems[21].
| Expert picks: What To Read Next |
|---|
| Habit Stacking: A Behavioral Strategy to Build Healthy Habits in 2026 |
| What’s The Best Magnesium For Anxiety? |
Your Genes Influence How Nicotine Affects You
One dimension of this conversation that receives almost no attention in biohacking circles is individual genetic variation in nicotine metabolism.
The primary enzyme metabolizing nicotine is CYP2A6, encoded by a highly polymorphic gene.
Variation in CYP2A6 leads to dramatically different rates of nicotine clearance among individuals, classified as normal, intermediate, slow, and poor metabolizers[22].
Fast (normal) metabolizers clear nicotine rapidly, experience more frequent cravings, and tend to smoke more cigarettes, or, in a pouch context, to use more frequently and at a higher risk of compulsive use[23].
Slow metabolizers retain nicotine in circulation longer, are exposed to higher peak concentrations per dose, and paradoxically tend to smoke less and show better cessation outcomes on nicotine patch therapy. But they also face greater cardiovascular exposure per dose consumed[24].
This means the same pouch that produces mild alertness in one person can trigger intense craving or cardiovascular stress in another.
Twin studies estimate that nicotine dependence, withdrawal symptoms, and smoking behaviors are between 31% and 60% heritable.
What Responsible Science Actually Looks Like
None of this means nicotine has no scientific interest whatsoever.
Researchers, including Newhouse, continue investigating nicotine-based interventions in carefully defined clinical populations: people with mild cognitive impairment, individuals with ADHD, Parkinson's patients, under controlled conditions, with pre-registered outcomes and peer-reviewed publication.
That is responsible science: specific populations, controlled protocols, measurable outcomes, and transparent publication.
It is not the same as a biohacker instructing millions of followers to cut a patch in half and self-experiment.
The Alzheimer’s Drug Discovery Foundation rates nicotine as having limited and inconclusive evidence for cognitive benefit, with findings from small, short-term studies that require replication, and highlights risks such as addiction and potential cardiovascular effects as important safety concerns[25].
The Foundation notes that while nicotine replacement therapy is validated for smoking cessation, its actual approved use, evidence for use in healthy individuals as a cognitive enhancer is not established.
What the Evidence Actually Supports: A Summary
- Short-term attention and alertness improvements from nicotine in acute settings are real but modest, primarily studied in smokers or people with cognitive impairment, not in healthy adults.
- No evidence supports nicotine preventing or reversing Alzheimer's disease in healthy people. The Cochrane review found no reliable evidence as a treatment for those with the disease.
- The smoking-Parkinson's correlation is real but poorly understood. Clinical trials of nicotine for Parkinson's have failed, and the protective agent in tobacco may not be nicotine.
- Regular nicotine use in previously non-dependent people creates dependence with high predictability, eliminating any cognitive benefit and creating a new health burden.
- Nicotine carries real cardiovascular risks in non-smokers, endorsed by both the European Society of Cardiology (2024) and the American Heart Association.
- Your CYP2A6 genotype largely influences how nicotine behaves in your body. No population-level claim about nicotine's "health effects" is valid without accounting for this variation.
The medical community is not recommending nicotine as a health supplement.
That is not because the establishment is suppressing inconvenient truths.
It is because the evidence does not meet the bar required for a clinical recommendation, especially for a substance that is highly addictive and carries cardiovascular risk in previously non-dependent users.
When it comes to your health, the standard should be evidence, not virality.
FAQs
Nicotine may improve attention temporarily, but there is no strong evidence that it enhances long-term cognition in healthy individuals.
No. Current clinical evidence does not support nicotine as a treatment or preventive strategy for Alzheimer’s disease.
Although some studies show lower Parkinson’s rates in smokers, nicotine itself has not proven effective in clinical trials and is not recommended for prevention.
They are safer than cigarettes in terms of cancer risk, but they still carry risks such as addiction and negative cardiovascular effects.
Nicotine is highly addictive and can lead to dependence quickly, even in people who have never smoked before.
Yes. Variations in the CYP2A6 gene influence how quickly nicotine is processed, affecting addiction risk and overall health impact.
References
- https://www.nytimes.com/2026/04/20/well/nicotine-health-maha.html
- https://tobaccomonitoring.org/wp-content/uploads/2025/10/Nicotine-Pouch-Sales-Data-Brief_8.10.2025.pdf
- https://hsph.harvard.edu/news/u-s-smoking-rate-hits-an-all-time-low-but-theres-still-work-to-do/
- https://www.cspdailynews.com/tobacco/tucker-carlson-launches-nicotine-pouch-brand
- https://pmc.ncbi.nlm.nih.gov/articles/PMC7554201/
- https://www.medrxiv.org/content/10.64898/2025.11.27.25341175v1.full
- https://pmc.ncbi.nlm.nih.gov/articles/PMC2773651/
- https://journals.sagepub.com/doi/10.1177/1178221820926545
- https://www.tandfonline.com/doi/full/10.1080/13607863.2019.1647140#d1e354
- https://iris.who.int/bitstream/handle/10665/128041/WHO_NMH_PND_CIC_TKS_14.1_eng.pdf
- https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0118333
- https://pubmed.ncbi.nlm.nih.gov/10796667/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC9019319/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC2815339/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC12384040/
- https://www.fda.gov/tobacco-products/health-effects-tobacco-use/nicotine-why-tobacco-products-are-addictive
- https://www.ncbi.nlm.nih.gov/books/NBK236759/
- https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaf1010/8377624
- https://www.ahajournals.org/doi/10.1161/CIR.0000000000001293
- https://hsph.harvard.edu/news/zyn-pouches-safer-than-smoking-but-still-pose-risks/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC12675456/
- https://www.mdpi.com/2075-4426/7/4/18
- https://pubmed.ncbi.nlm.nih.gov/15735609/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC9122756/
- https://www.alzdiscovery.org/uploads/cognitive_vitality_media/addf-nicotine-full-report.pdf
